Skip to main content
. Author manuscript; available in PMC: 2024 Jun 18.
Published in final edited form as: Cancer Cell. 2023 Nov 2;41(11):1972–1988.e5. doi: 10.1016/j.ccell.2023.10.006

Figure 1. Baseline Composition of Micro-Environment by Tissue Site.

Figure 1.

(A) Phase 2 trial design schema.

(B) Uniform manifold projection (UMAP) plot constructed from VIPER-inferred protein activity of all cells in aggregate across baseline pre-treatment patient samples. Cells are clustered by resolution-optimized Louvain algorithm with cell type inferred by SingleR.

(C) Stacked barplot of the frequency of each major cell lineage within each baseline patient sample, with each column representing a unique patient and patients grouped by metastatic site. Cell clusters from B are aggregated by shared cell type.

(D) Stacked barplot of immune vs. non-immune cell frequencies, from C.

(E) Boxplot showing distribution of frequencies for each cell cluster in B at baseline, comparing tissue sites. Also see Figure S1.